ProMIS Neurosciences to Present at Guggenheim Securities SMID Cap Biotech Conference
Key Insights
ProMIS Neurosciences will participate in a fireside chat at the Guggenheim Securities SMID Cap Biotech Conference on February 5, 2025.
CEO Neil Warma will represent ProMIS, discussing the company's focus on antibody therapeutics for neurodegenerative diseases.
A live webcast of the fireside chat will be available on the company's website for at least 30 days following the event.
ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focusing on antibody therapeutics for neurodegenerative diseases, announced that CEO Neil Warma will participate in a fireside chat at the Guggenheim Securities SMID Cap Biotech Conference on February 5, 2025, in New York, NY.
The company's focus is on developing treatments for diseases like Alzheimer’s disease (search) (AD), amyotrophic lateral sclerosis (search) (ALS), and multiple system atrophy (search) (MSA) by targeting toxic misfolded proteins.
ProMIS's Therapeutic Approach
ProMIS Neurosciences utilizes its proprietary target discovery engine, incorporating a thermodynamic, computational platform known as ProMIS™ and Collective Coordinates, to identify Disease Specific Epitopes on misfolded proteins.
Lead Candidate: PMN310
The company's lead product candidate, PMN310, is a humanized monoclonal antibody designed to selectively bind toxic Aβ oligomers (search) without binding to plaque or monomers. This specificity is crucial, as oligomers are known to drive disease progression in AD. PMN310 has completed a Phase 1a clinical study and has entered Phase 1b clinical trials in AD patients. The design of PMN310 is expected to support enhanced safety and efficacy by precisely targeting the toxic oligomers implicated in Alzheimer's disease progression.